A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

Also called NCT04075916

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 201 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04075916
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04075916. Allocation not applicable; no masking; primary purpose treatment. Start 2021-06-22 (actual); primary completion 2025-07-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
Acronym
THINKER-NEXT
Condition
End Stage Renal Disease
Intervention (Drug)
Epclusa
Lead sponsor
University of Pennsylvania (class: other)
Collaborator
Gilead Sciences (class: industry)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct04075916
Content hash
32d7c0edf0f1277459c3f9796ea959d6ad784c0c3f2c561794e66c177206cac1